DBDetlef Klaus Bartsch

Detlef Klaus Bartsch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Detlef Klaus Bartsch has a total of 488 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Implementation of transoral robotic thyroid surgery in a European tertiary center

    by Detlef K Bartsch, Elias Karakas, Björn Schwedhelm, Isabel Zink, Karl M Meggiolaro, Elisabeth Maurer

    Transoral thyroidectomy via vestibular approach has gained increasing acceptance due to its excellent cosmetic outcomes. Transoral robotic thyroidectomy (TORT) represents a further technical evolution, potentially offering enhanced options of instrument movement and visualization. However, no reports from Europe were yet published. We report the first TORT performed in Germany in a 56-year-old female presenting with a symptomatic 20 × 16 mm sized nodule in the right thyroid lobe measuring 14 ml. A right hemithyroidectomy was performed using TORT with the daVinci Xi® robotic system. Total operative time was 230 min. The postoperative course was uneventful, and the patient was discharged on postoperative day 3. TORT is feasible and safe in selected patients also in the German hospital setting, although the additional costs are not reimbursed by the German health system. This case demonstrates the technical applicability and highlights key procedural steps for implementation.

  • Open Access

    Characteristics, management, and outcomes of patients with VIPoma –A retrospective analysis of the ENETS database

    by Detlef K. Bartsch, L. Mais, L. de Mestier, E. Baudin, G. Kaltsas, J. Hofland, R. Garcia‐Carbonero, E. Tiensuu Janson, M. G. McNamara, M. Andreassen, et al.

    Introduction: VIPoma is an extremely rare functioning pancreatic neuroendocrine tumor. Therefore, data regarding treatment and outcome are very limited. Aim (s): This multicenter study aimed to analyze clinical characteristics, real‐world management, and outcomes of patients with VIPoma. Methods: Patients with VIPoma treated in a 20‐year period at 14 referral centers for neuroendocrine tumors (NET) were collected in the ENETS Database. Clinical characteristics, therapeutic interventions, and outcomes were analyzed retrospectively. Disease‐free survival (DFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Results: Of 70 patients, 59 (54% male) with a median age of 55 years were included. Forty‐six (78%) patients were diagnosed due to the classical watery diarrhea–hypokalemia–achlorhydria (WDHA) syndrome, and 40 (68%) presented with distant metastases at diagnosis. Fifty‐two (88%) had serum VIP levels >2 times the upper normal limit and the median Ki‐67 index was 5% (range 1%–40%). Surgery of the primary VIPoma was performed in 32 (54%), with curative intent in 22 (37%). In patients with stage I–III disease ( n = 19), long‐term cure was achieved in only 26% (5/19), with a median DFS of 81 (95%‐CI: 1–215) months and 10‐year OS of 78% (95%‐CI: 61%–100%). In stage IV patients ( n = 53, 40 at diagnosis, 13 disease progression), the sequence and type of 354 treatment lines varied, while SSA ( n = 77, 22%), loco‐regional liver‐directed therapy ( n = 72, 20%), and chemotherapy ( n = 69, 19%) were most often applied. Median OS for patients with stage IV at diagnosis was 142 (95%‐CI: 87–not available (NA)) months with 10‐year survival of 50% (95%‐CI: 35%–73%). Conclusion: Patients with VIPoma treated at NET centers have relatively favorable survival, even with distant metastases at diagnosis, although long‐term cure rates remain low.


  • Open Access

    Detection, identification and quantification of NGTs in EU authorization procedures – No solution without legislative change

    by Kai Purnhagen, Detlef Bartsch, Kolja Eckermann, Aleksandra Hubar-Kołodziejczyk, Jörn Lämke, Steffen Pallarz, Justus Wesseler

    For the purposes of GMO authorisation, applicants are required to submit validated methods for the detection, identification and quantification (DIQ). For classical transgenic organisms, this requirement has proven workable. For products derived from New Genomic Techniques (NGTs), specifically those introducing small insertions and deletions (InDels) without foreign genetic material, it has not. NGT-induced genomic changes are frequently indistinguishable from naturally occurring mutations, making identification legally required but technically unachievable with currently available analytical tools. This open letter examines whether recently proposed DIQ methodologies, including genomic fingerprinting approaches based on single nucleotide variant (SNV) profiling, can bridge this gap. We find that while such approaches advance detection capabilities, they fall short of the identification and quantification standards demanded by EU law, for reasons such as the absence of universal pangenome datasets, the complexity of polyploid crop genomes, the loss of fingerprint integrity through elite line crossing, and the dependence of recombination rates on multiple species-specific factors. The mismatch between legal requirements and scientific feasibility has consequences for authorisation procedures, supply chain compliance, organic farming integrity, and international trade. We conclude that no purely technical solution is forthcoming and that legislative change is necessary. Aligning the EU’s evidentiary standards with technical reality is a precondition for a functional and enforceable GMO authorisation system.

  • Open Access

    Optimized precision oncology through implementation of a comprehensive molecular analysis pipeline – relevance for additional therapeutic options

    by Nuwar Harb, Marcel Romey, Albert Grass, Florentin von Kügelgen, Akira Hattesohl, Jonas A. Schäfer, Lukas Frey, Elisabeth Mack, Anja Rinke, Cornelia Brendel, et al.


  • Open Access

    OMW: Inzidentalom der Nebenniere

    by Detlef K. Bartsch

  • Open Access

    Adrenokortikales Karzinom (ACC): aktuelle chirurgische Therapieprinzipien

    by Detlef K. Bartsch

    Zusammenfassung Das adrenokortikale Karzinom (ACC) zählt zu den seltensten soliden Tumoren, weist aber eine ausgeprägte biologische Aggressivität und ein hohes Rezidivpotenzial auf. Die vollständige Tumorresektion (R0) stellt die einzige kurative Therapieoption dar und bestimmt maßgeblich das Langzeitüberleben. Aufgrund der funktionellen Heterogenität der Tumoren sowie der häufig bestehenden Kortisol- oder Androgenexzesse müssen präoperative Diagnostik und perioperative Betreuung in enger interdisziplinärer Zusammenarbeit erfolgen. Die offene Adrenalektomie gilt weiterhin als Goldstandard, während minimalinvasive Verfahren in streng selektionierten Fällen und in ausgewiesenen Hochvolumenzentren vertretbar sind. Die Bedeutung einer systematischen Lymphadenektomie nimmt zu, auch wenn deren optimales Ausmaß noch nicht abschließend definiert ist. Postoperativ richtet sich die adjuvante Therapie nach der individuellen Risikokonstellation. Mitotan ist in Fällen mit intermediärem und hohem Rezidivrisiko indiziert. Rezidive treten häufig auf und sollten, sofern technisch möglich, chirurgisch behandelt werden. In metastasierten Stadien stehen multimodale Konzepte im Vordergrund, die chirurgische, interventionell-radiologische und systemische Therapien kombinieren. Insgesamt bleibt die Prognose limitiert, allerdings stellen die chirurgische Expertise und die Behandlung in spezialisierten Zentren entscheidende Determinanten für eine verbesserte Prognose dar.